Page 59 - 2020_07-Haematologica-web

Diagnosis and treatment of acquired hemophilia A
factor VIII deficiency presenting with com- partment syndrome. Am J Emerg Med. 2014;32(2):195.
34. Dachman AF, Margolis H, Aboulafia E. Does Sjogren's syndrome predispose surgical patients to acquired hemophilia? J Am Osteopath Assoc. 1995;95(2):115-118, 121.
35. Lusher JM. Early treatment with recombi- nant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl. 1998;63:7-10.
36. Delgado J, Jimenez-Yuste V, Hernandez- Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on thera- py and prognostic factors. Br J Haematol. 2003;121(1):21-35.
37. Tiede A, Worster A. Lessons from a system- atic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. Ann Hematol. 2018;97(10): 1889-1901.
38. Tiede A, Giangrande P, Teitel J, et al. Clinical evaluation of bleeds and response to haemo- static treatment in patients with acquired haemophilia: a global expert consensus statement. Haemophilia. 2019;25(6):969- 978.
39. Seita I, Amano K, Higasa S, Sawada A, Kuwahara M, Shima M. Treatment of acute bleeding episodes in acquired haemophilia with recombinant activated factor VII (rFVIIa): analysis from 10-year Japanese postmarketing surveillance. J Thromb Haemost. 2013;11(Suppl. 2):119.
40. Dimichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia. 2006;12(4):352-362.
41. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007;13(3):249-255.
42. Tjonnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the man- agement of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag. 2007;3(4):527-531.
43. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activi- ty. Haemophilia. 2004;10(2):169-173.
44. Zanon E, Milan M, Gamba G, et al. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: a sequential study. Thromb Res. 2015;136(6):1299-1302.
45. Arokszallasi A, Razso K, Ilonczai P, et al. A decade-long clinical experience on the pro- phylactic use of activated prothrombin com- plex concentrate in acquired haemophilia A: a case series from a tertiary care centre. Blood Coagul Fibrinolysis. 2018;29(3):282- 287.
46. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant fac- tor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2(10): 1700-1708.
47. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic
adverse events. Haemophilia. 2002;8(2):83-
90.
48. Giangrande PL. Porcine factor VIII.
Haemophilia. 2012;18(3):305-309.
49. Turkantoz H, Konigs C, Knobl P, et al. Cross- reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01/2010 study. J
Siegert G, Ehninger G, Platzbecker U. Successful eradication of acquired factor- VIII-inhibitor using single low-dose ritux- imab. Haematologica. 2010;95(3):521-522.
64. XuY,ZhangX,ZhaoY,ZhaoL,QiuH,Wu D. Successful treatment of a patient with acquired haemophilia A with a combination of a low-dose rituximab and recombinant human FVIIa. Haemophilia. 2013;19(2):e95-
Thromb Haemost. 2020;18(1):36-43.
50. Tarantino MD, Cuker A, Hardesty B, 96.
Roberts JC, Sholzberg M. Recombinant
porcine sequence factor VIII (rpFVIII) for
acquired haemophilia A: practical clinical
experience of its use in seven patients. 486.
Haemophilia. 2017;23(1):25-32.
51. EMC. Summary of Product Characteristics -
DDAVP/Desmopressin Injection 2019. Available from: https://www.medicines. org.uk/emc/product/5447/smpc [Accessed 13 Apr 2020].
52. Baxter Corp. FEIBA VH, Anti-inhibitor coag- ulant complex, Vapor-Heated. Summary of Product Characteristics 2005; Available from: https://www.rxlist.com/feiba-vh- drug.htm [Accessed 13 Apr 2020].
53. Holmstrom M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience. Haemophilia. 2012;18(4):544-549.
54. Baudo F, de Cataldo F. Acquired hemophilia: a critical bleeding syndrome. Haematologica. 2004;89(1):96-100.
55. Pharmaceuticals and Medical Devices Agency Japan. Annual Report FY 2014. Available from: http://www.pmda.go.jp/ files/000208305.pdf [Accessed 13 Apr 2020]
56. EMA. Summary of Product Characteristics - Hemlibra 2018; Available at https://www.ema.europa.eu/en/docu- ments/product-information/hemlibra-epar- product-information_en.pdf ; Accessed 13 Apr 2020.
57. Knoebl P, Sperr WR, Schellongowski P, et al. Emicizumab for the treatment of acquired hemophilia A: lessons learned from 4 very different cases. Blood. 2018;132(Suppl 1):2476.
66. EMA. Summary of Product Characteristics - MabThera 2018. Available at: https://www.ema.europa.eu/documents/pr oduct-information/mabthera-epar-product- information_en.pdf [Accessed 13 Apr 2020].
67. Tran H, Brighton T, Grigg A, et al. A multi- centre, single-arm, open-label study evaluat- ing the safety and efficacy of fixed dose rit- uximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol. 2014;167(2):243-251.
68. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121(11): 1976-1981.
69. EMA. Summary of Product Characteristics - Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion 2017. Available at: https://www.medicines. org.uk/emc/product/3526/smpc [Accessed 13 Apr 2020].
70. Obaji S, Rayment R, Collins PW. Mycophenolate mofetil as adjunctive thera- py in acquired haemophilia A. Haemophilia. 2019;25(1):e59-e65.
71. Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmo protocol: documentation of an in vivo immunomodulating concept. Blood. 2005;105(6):2287-2293.
72. Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica. 2000;85(10 Suppl):64-68.
73. Lian EC, Villar MJ, Noy LI, Ruiz-Dayao Z. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and pred- nisone. Am J Hematol. 2002;69(4):294-
58. Mohnle P, Pekrul I, Spannagl M, Sturm A,
Singh D, Dechant C. Emicizumab in the
treatment of acquired haemophilia: a case
report. Transfus Med Hemother. 2019;46(2):
121-123. 295.
59. Hay CR. Acquired haemophilia. Baillieres Clin Haematol. 1998;11(2):287-303.
60. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987;147(6):1077-1081.
61. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006;133(6):591-605.
62. Mumoli N, Giorgi-Pierfranceschi M, Ferretti A, Vitale J, Cei M. Acquired hemophilia treated using low-dose of rituximab. J Am Geriatr Soc. 2016;64(8):1744-1745.
63. Wermke M, von Bonin M, Gehrisch S,
74. Huth-Kuhne A, Lages P, Hampel H, Zimmermann R. Management of severe hemorrhage and inhibitor elimination in acquired hemophilia: the modified Heidelberg-Malmö protocol. Haematologica. 2003;88(S12):86-92.
75. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) fac- tor VIII inhibitors with high-dose intra- venous gammaglobulin. Blood. 1995;86(2): 797-804.
76. Schunemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospi- talized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-3225.
65. Yao Q, Zhu X, Liu Y, et al. Low-dose ritux- imab in the treatment of acquired haemophilia. Hematology. 2014;19(8):483-
haematologica | 2020; 105(7)
1801